tbuckley/cabot-search huggingface dataset:
SAT0404 Evaluation of The Clinical Usefulness of A Standardized Dose Reduction Protocol for Maintenance of Remission in Patients with As under anti-TNF Treatment: Table 1
Authors: M. Arévalo Salaet, M. Aparicio, C. Pontes, F. Torres, T. Salman, F. Blanco, A. Sellas, R. Sanmarti, J. Gratacos
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To assess if reduced dose of iTNF is not less effective than complete dose for response maintaining <h3>Methods</h3> Prospective, randomized, multicenter, real life open-label study of non-inferiority coordinated by Spanish Societies of Clinical Pharmacology and Rheumatology. Patients included were randomized (1:1) in a complete dose arm (C) or in a reduced dose arm according to a previous standardized protocol (E). The primary objective was the proportion of patients who after a year of following maintained the acceptable therapeutical goal (ATG) (BASDAI, physicianVAS, patientVAS, night axial pain all &lt;4). Secondary endpoints were: proportion of patients with clinical remission) (BASDAI, physicianVAS, patientVAS, night axial pain all &lt;2), disease activity assessed with ASAS, BASFI and quality of life. The main analysis was made per protocol (PP), considering an ATG percentage in C group of 87% with a maximum settled difference between both treatments inferior than 17% <h3>Results</h3> 113 AS, 84% men, age of 4596y and mean disease duration of 1395y. 22 (40%) were treated with adalimumab, 19 (35%) with etanercept, 10 (27%) with infliximab and 4 (7%) with golimumab. Main results are shown in table1. At 12 months follow-up 48 (82.8%) in the full dose arm vs 47 (85.5%) in reduced dose arm maintained the ATG demonstrating the non inferiority hypothesis (p=ns, dif -2.5%, 95%CI -16.6 to 11.7%). We did not observe also any significant difference in any of the rest of variables analyzed including the proportion of patients in remission and safety issues. Although 30% of patients showed ≥1 flare, without differences between both treatment arms, less than 15% required treatment dropout. <h3>Conclusions</h3> In patients with persistent clinical remission, dose reduction is not inferior to the standard dose. The presence of clinical flare is not uncommon, although less than half of cases lead to a change in the treatment. <h3>Disclosure of Interest</h3> None declared
SAT0011 Replication of A Distinct Psoriatic Arthritis Risk Variant at IL23R
Authors: A. Budu-Aggrey, J. Bowes, S. Lohr, S. Uebe, M.I. Zervou, P. Helliwell, A.W. Ryan, D. Kane, E. Korendowych, E. Giardina, J. Packham, R. McManus, O. FitzGerald, N. McHugh, F. Behrens, H. Burkhardt, U. Huffmeier, P. Ho, J. Martin, S. Castañeda, G. Goulielmos, A. Reis, A. Barton
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Psoriatic arthritis (PsA) is an inflammatory arthritis that is associated with psoriasis. Although the majority of PsA genetic risk loci identified also confer risk for psoriasis, we have recently reported evidence of loci that are associated with PsA and not psoriasis, including an association at the <i>IL23R</i> locus which is also independent of a psoriasis variant at the same locus. <h3>Methods</h3> The PsA-specific SNP rs12044149, and the psoriasis SNP rs9988642 at the <i>IL23R</i> locus were genotyped in a cohort of 914 PsA cases and 6,945 controls from Spain, Crete, Germany and the UK, with the Life Technologies QuantStudio genotyping platform. Association testing was carried out using PLINK, and a meta-analysis was performed with PsA Immunochip data (1,962 cases, 8,923 controls). Genotype data was also available from the psoriasis WTCCC2 study (excluding known PsA, n=1,784) to compare effect sizes between PsA and psoriasis using multinomial logistic regression in Stata, and to directly compare PsA and psoriasis genotypes. Credible SNP sets were calculated for the PsA and psoriasis <i>IL23R</i> associations using the Bayesian refinement method, and functionally annotated. <h3>Results</h3> We replicated the association rs12044149 with PsA (<i>P</i>=4.03x10<sup>–6</sup>), which remained significant when conditioning upon the psoriasis variant, rs9988642 (<i>P</i><sub>cond</sub>=4.86x10<sup>–6</sup>), and reached genome-wide significance during meta-analysis of the combined PsA dataset (<i>P</i><sub>meta</sub>=4.76x10<sup>–20</sup>). Only a modest association was found for rs9988642 (<i>P</i>=0.04), with no genome-wide significance found during meta-analysis (<i>P</i>=4.61x10<sup>–4</sup>). Within the psoriasis dataset, this association remained significant when conditioning upon rs12044149 (<i>P</i>=1.0x10<sup>–07</sup> vs. <i>P</i><sub>cond</sub>=1.63x10<sup>–5</sup>). Effect estimates for rs12044149 were significantly different between PsA and psoriasis (<i>P</i>=2.0x10<sup>–3</sup>), and direct comparison of genotypes for PsA and psoriasis found the risk allele to be significantly increased in PsA (<i>P</i>=4.52x10<sup>–4</sup>, OR=1.3). Credible SNPs for rs12044149 mapped to promoter and enhancer regions within memory CD8<sup>+</sup> T cells, which we have previously reported to be critical for PsA. <h3>Conclusions</h3> We have successfully replicated a PsA-specific (associated with PsA but not psoriasis) risk variant at the <i>IL23R</i> locus in an independent cohort, confirming rs12044149 to be distinct from rs9988642 (r<sup>2</sup>=0.02). This gives five PsA-specific associations that have now been identified. <h3>Disclosure of Interest</h3> None declared
OP0064-HPR A Model Including Foot-Related Factors Impacting on Quality of Life (QOL) in Systemic Sclerosis
Authors: B.A.-P. Alcacer-Pitarch, A. Redmond, F. Del Galdo, M. Buch, A.-M. Keenan
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> While foot problems in patients with systemic sclerosis (SSc) have been described previously and the association with disability noted, the impact of such problems on the quality of life (QoL) in people living with SSc has yet to be quantified. <h3>Objectives</h3> To identify the factors, including those arising from foot pathology, that impact on QoL in SSc. <h3>Methods</h3> Structural equation modelling (SEM) was used to explore the multifactorial pathways impacting on QoL in a cross section cohort of people with SSc. Potential candidate factors were identified through: i) a literature review with expert consultation; and ii) a cross-sectional study capturing clinical features. QoL was measured using the disease-specific SScQoL questionnaire. <h3>Results</h3> One hundred and twenty one patients with SSc were recruited (106 female; median age 59, ranges 25 to 86 years) with a median disease duration of nine years (IQR:4,13) and a median modified Rodnan Skin Score of 2 (IQR:0, 5). The model that best explained the factors contributing to the SSc impact on QoL showed complex inter-relationships between 11 factors (Figure1) (c2=37.022, df=37, p=0.468, RMSEA=0.002, GFI=0.951, CFI=1.000). Combined, these factors explained 84% of the impact on QoL (R<sup>2</sup> =0.84) in patients with SSc. General disease factors, including physical function (standardised total effect 0.64), breathing problems (standardised total effect 0.493), and depression (standardised total effect 0.428) had the greatest impact. Foot problems had a substantial but indirect effect on quality of life (foot function and foot pain standardised total effect 0.343 and 0.327). A summary of the effects of the factors included in the model is provided in the Table 1. <h3>Conclusions</h3> The impact of SSc on QoL is substantial and complex. While loss of physical function is the most influential factor on QoL, followed by breathing difficulty and depression, foot problems significantly contribute to this impact. <h3>Disclosure of Interest</h3> None declared
Multiple Myeloma and Infections: A Population-Based Study Based On 9,610 Multiple Myeloma Patients
Authors: Cecilie Blimark, Ulf-Henrik Mellqvist, Ola Landgren, Magnus Björkholm, Malin L Hultcrantz, Christian Kjellander, Ingemar Turesson, Erik Holmberg, Sigurdur Y Kristinsson
Journal: Blood (2012)
Survival Benefit of Post Induction Consolidation Therapy in MCL (Mantle Cell Lymphoma): a Polish Lymphoma Research Group (PLRG) Retrospective Multicenter Analysis
Authors: Wojciech Jurczak, Agnieszka Giza, Dorota Krochmalczyk, Dagmara Zimowska-Curylo, Marcin Sobocinski, Beata Stella-Holowiecka, Aleksandra Holowiecka-Goral, Piotr Boguradzki, Elzbieta Kisiel, Grzegorz Mazur, Tomasz Wrobel, Wanda Knopinska-Posluszny, Ewa Kalinka - Warzocha, Aleksander B. Skotnicki
Journal: Blood (2008)
Statin Medication Enhances Progression of Coronary Artery Calcification
Authors: Iryna Dykun, Nils Lehmann, Hagen Kälsch, Stefan Möhlenkamp, Susanne Moebus, Thomas Budde, Rainer Seibel, Dietrich Grönemeyer, Karl-Heinz Jöckel, Raimund Erbel, Amir A. Mahabadi
Journal: Journal of the American College of Cardiology (2016)
PTU-115 Pan-Enteric Prolongation of Transit Times and Heightened Caecal Fermentation is Present in Type 1 Diabetic Patients with Peripheral Neuropathy: Abstract PTU-115 Table 1
Authors: AD Farmer, SD Mohammed, M Scott, A Drewes, C Brock
Journal: Gut (2016)

<h3>Introduction</h3> The wireless motility capsule (WMC) is a minimally invasive ambulatory technology that concurrently measures pressure, pH and temperature as it traverses the gastrointestinal (GI) tract. Knowledge gaps remain concerning GI motility in type 1 diabetes (T1DM) with established diabetic sensorimotor polyneuropathy (DSPN). It has been recently suggested that the change in pH across the ileocaecal valve (ICV) is a surrogate marker of bacterial fermentation in’the caecum.<sup>1</sup> The aim was to explore whether T1DM patients with DSPN have demonstrable GI dysmotility with in comparison to matched healthy controls. Furthermore, we aimed to investigate the co-relationships between motility, self-reported GI symptoms, quality of life and objective markers of DSPN. <h3>Methods</h3> 41 patients with T1DM with DSPN (33 male, mean age 51 years, range 35–71) and 41 healthy controls (28 male, mean age 51 years, range 28–78) underwent a WMC study using a standardised protocol following consumption of a meal of known nutritional composition (SmartBar).<sup>2</sup> Segmental transit was derived from measures around known anatomical landmarks as identified by compartmental pH changes. In patients, vibration thresholds and the Michigan Neuropathy Screening Instrument (MNSI) were collected in conjunction with self-reported GI symptoms (Patient Assessment of Upper Gastrointestinal Disorder Severity Symptom Index (PAGI-SYM)). <h3>Results</h3> Differences in regional and whole gut transit times are shown in Table 1. ICJ pH drop was associated with prolonged colonic transit (r = 0.34, <i>p</i> = 0.01). Multivariate linear regression, controlling for age, gender, duration of T1DM and glycaemic control, did not demonstrate an association between PAGI-SYM, regional or total transit times but higher vibration thresholds and MSNI were associated with prolonged gastric emptying time (<i>p</i> = 0.03, <i>p</i> = 0.002 respectively). <h3>Conclusion</h3> T1DM is associated with prolongation of regional and whole gut transit prior to the development symptoms independent of disease duration and glycaemic control. Moreover, such prolongation is associated with clinical markers of DPSN. Further work is warranted to examine the longitudinal nature of these findings and whether pharmacotherapeutic interventions can lead to the restoration of normal motility. <h3>References</h3> 1 Farmer, <i>et al</i>. <i>WJG</i> 2014. 2 Wang YT, <i>et al. APT</i> 2015. <h3>Disclosure of Interest</h3> None Declared
AB0596 Assessment of Pulmonary Function in Patients Diagnosed of Early Systemic Sclerosis
Authors: F.M. Ortiz Sanjuan, J. Ivorra Cortés, L. González Puig, I. Chalmeta Verdejo, E. Grau Garcia, M. Fernández Matilla, C. Feced Olmos, E. Labrador Sánchez, K. Arévalo Ruales, R. Negueroles Albuixech, J. Fragio Gil, I. Martínez Cordellat, J. Valero Sanz, C. Alcañiz Escandell, C. Nájera Herranz, G. Poveda Marín, J. Román Ivorra
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Interstitial lung disease (ILD) is a frequent complication of systemic sclerosis (SSc) and is often progressive and has a poor prognosis. A restrictive ventilatory defect could suggest ILD either alone or in combination with pulmonary arterial hypertension. Nowadays, Early-SSc is well defined as preliminary stage of SSc. Patients who meet criteria for Early-SSc could benefit from an early diagnosis of pulmonary involvement. <h3>Objectives</h3> Our aim was to assess the pulmonary function in patients diagnosed of Early SSc. <h3>Methods</h3> Retrospective observational study of a wide and unselected series of patients diagnosed as Early-SSc from a single university hospital from June 2012 to August 2015. Patients were classified as Early-SSc following Le Roy criteria. In spite of this, patients already did not met 2013 ACR/EULAR classification criteria for SSc. We reviewed pulmonary function through conventional spirometry and diffusing capacity of lung for carbon monoxide (DLCO). Interpretation of the results of spirometry and DLCO was made according European Respiratory Society (ERS) and American Thoracic Society (ATS) standards <h3>Results</h3> We included a total of 41 patients with a mean age of 53±15.6 years (97.6% women; 2.4% men). No one of our patients evidenced a restrictive ventilatory pattern. DLCO was under normal limits in 11 patients (26.8%). Small airway obstruction expressed according decreased maximal (mid-) expiratory flow (MMEF) 25–75 was present in 13 patients (31.7%). After a mean follow-up period of 26.1±16.6 months, 20 (48.8%) patients fulfilled 2013 ACR/EULAR criteria. The remaining 21 patients continued classified as Early-SSc following Le Roy criteria. The analysis of the subgroup of patients who progressed to SSc showed that DLCO was decreased in 7 of those 20 patients (35%) and also 8 of 20 patients (40%) presented decreased maximal (mid-) expiratory flow (MMEF) 25–75. Comparing with the subgroup of patients which not progressed to SSc no were significant differences (Decreased DLCO: 35% vs 26.8%; p=0.8 and Decreased MMEF 25–75: 40% vs 31.7%; p=0.9). <h3>Conclusions</h3> In our study, about a quarter of the patients classified as Early-SSc presented abnormal values of DLCO and/or signs of small airway obstruction without the presence of a restrictive ventilatory pattern. Moreover, the expression of this pulmonary dysfunction tends to be more frequent in patients who progressed to definitive SSc, although this was not statistically significant. An early assessment of pulmonary function in this context should be highly recommended. <h3>Disclosure of Interest</h3> None declared
Enhancing the Acute Hemostatic Efficacy in Cynomolgus Monkeys By Targeting Activated Coagulation Factor VII to Platelets
Authors: Siyuan Tan, Joe Salas, Kai Chen, Tamera Ashworth, Sarah Smith, Elena Kistanova, Nancy Moore, Marisol Acosta, Anxhela Kole, David R. Light, Robert Peters, Haiyan Jiang
Journal: Blood (2014)
AB0228 Arthritis with Childhood Onset in Adult Patients: Long-Term Outcomes and Social Adaptation
Authors: N. Muravieva, Y. Muraviev
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Follow-up care and social adaptation issues in adult patients with childhood onset arthritis are highly relevant, as the prognosis and long-term outcomes of the disease are not sufficiently studied. <h3>Objectives</h3> To assess long-term outcomes and social status of adults with childhood onset arthritis. <h3>Methods</h3> Establishment of the adult patients with childhood onset arthritis database, covering the period from 2003 year to 2015 year, allowed to analyze the disease activity, the radiographic stage and functional class (using <i>Steinbrocker method</i>), complications, used pharmacotherapies, as well as social status (education, professional activity, marital status). <h3>Results</h3> The database includes 235 patients: 176 females, 59 males, mean age 27.7±8.0 years, disease duration 18.1±8.5 years. Persisting arthritis was found in 72% patients. Radiographic stage II was established in 139 patients, stage III – in 49, stage IV – in 47 patients. Functional class II predominates in the majority of patients. The most common disease-modifying anti-rheumatic drug (DMARD) used was methotrexate – in 73% of patients, each 3rd patient was taking sulfasalazine, each 4th - leflunomide, 15% of patients had never used whatever DMARDs. 53 patients were administered biologic drugs: 30 patients received 1, 16 patients – 2, 6 patients – 3, 1 patient received 4 of biologic drugs. Glucocorticoids (GCs) were administered in 55% of patients, more than 60% continue on GCs, including 42 patients using GCs for &gt;10 years. Aseptic bone necrosis (predominantly of femoral head) was reported in 25% of patients. Bone fractures were documented in 8 patients. Joint prosthetics were required in 23 patients: single joint – in 9, 2 joints – in 11, 3 joints – in 2, 4 joints - in one patient. Arterial hypertension, requiring medication, was found in 12 patients. Nanism was diagnosed in 27 patients, primary amenorrhea – in 11, secondary amenorrhea – in 2, steroid diabetes – in 2 patients. Light perception visual acuity was documented in 2 patients, poor vision was reported in 3 patients. Amyloidosis was found in 2 cases. At present higher education was finished or in the process of continuation by 49 patients (including 2 patients – in medical institute), special education was finished or in the process of continuation by 169 patients. Only school education has 17 patients. Out of those with full education (127 patients) 85 are working (including 2 rheumatologists and 1 pediatrician), while 42 patients are in dependence. 52 patients have family (93% - women), 36 patients (91% - women) have children: one – 27, two – 7, three – 1, six – 1. <h3>Conclusions</h3> Only 1/3 of adult patients with childhood onset arthritis have satisfactory long-term clinical outcomes; at the same time the majority of patients are well adapted socially. <h3>Disclosure of Interest</h3> None declared
Unexpected Diffuse 18F-NaF Uptake in the Lung Parenchyma in a Patient With Severe Hypercalcemia Due to Myelomatosis
Authors: Ali Asmar, Lene Simonsen, Birgitte Svolgaard, Jens Bülow
Journal: Clinical Nuclear Medicine (2016)

An 84-year-old man was admitted to the intensive care unit because of hypercalcemic crisis leading to acute renal failure needing dialysis. The patient had no other history of illness. However, because prostate-specific antigen levels were increased, the patient was referred to F-NaF PET/CT on suspicion of active skeletal metastases. The patient was finally diagnosed with myelomatosis. Although the skeletal uptake of F-NaF was without signs of focal metastasis, the F-NaF PET/CT scanning surprisingly revealed diffuse high accumulation of F-NaF in the lung parenchyma, possibly because of calcium deposition in the lung parenchyma associated to amyloidosis seen in patients with myelomatosis.
Abnormal Proplatelet Formation and Myosin Activation Status in Patients with MYH9-Related Syndrome
Authors: Yolande Chen, Siham Boukour, Paquita Nurden, Ababacar Seye, Olivier Bluteau, Alberta Palazzo, Yunhua Chang, Larissa Lordier, Remi Favier, Nicole Schlegel, Anne Galy, Alan T. Nurden, Hana Raslova, William Vainchenker, Najet Debili
Journal: Blood (2011)
Modulation of Hemodynamics and Adhesion of Sickle Red Blood Cells On Endothelial Cells Treated with Hydroxycarbamide.
Authors: Emmanuelle Verger, Sandrine Laurance, Arlette Bruel, Damien Schoëvaërt, Marie-Helene Odievre, Odile Feneteau, Claudine Lapouméroulie, Jacques Elion
Journal: Blood (2009)
HDAC Inhibition by LBH589 Affects Phenotype and Function of Human Dendritic Cells.
Authors: Weihua Song, Yu-Tzu Tai, Ze Tian, Teru Hideshima, Dharminder Chauhan, Puru Nanjappa, Mark A. Exley, Kenneth C. Anderson, Nikhil C. Munshi
Journal: Blood (2009)
Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial.
Authors: Paul G. Richardson, S. Jagannath, D.E. Avigan, M. Alsina, R.L. Schlossman, A. Mazumder, N.C. Munshi, I. Ghobrial, D. Doss, M.L. McKenney, M.G. Farrell, D.L. Warren, L.E. Lunde, B. Gourley, S. Vaccaro, C. Delaney, S. Pountney, C.S. Mitsiades, T. Hideshima, C. Byrne, R. Knight, A. Birner, T. Myers, E. Weller, K.C. Anderson
Journal: Blood (2006)
AB0011 HLA-DP Polymorphisms Play Protective Role in Systemic Lupus Erythematosus in Chinese Han Population
Authors: Z. Junlong, Z. Wenli, T. Anning, C. Lin, Y. Bin, W. Lanlan
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> With the application of Genome-Wide Association studies (GWAS), the SLE risk gene loci in HLA-DR and HLA-DQ are gradually revealed [1]. However, the association of HLA-DP polymorphisms with SLE is pretty few reported. Considering the variants in rs3077 and rs9277535 in HLA-DP region were estimated influenced the immune response by affecting antigen presentation of HLA class II molecules to CD4+ T cells [2], it is worthy to explore the role of HLA-DP polymorphisms in SLE. <h3>Objectives</h3> Exploring the effects of presently hot HLA-DP SNPs, rs3077 and rs9277525 on SLE. <h3>Methods</h3> 335 SLE patients and 635 healthy controls were recruited in present study. Genotyping was performed with polymerase chain reaction-high resolution melting (PCR-HRM) assay and the data was analyzed using SPSS19.0. <h3>Results</h3> A significantly positive correlation was observed between the SNP rs3077 and rs9277535 of HLA-DP and SLE susceptibility (rs3077, OR=0.74, 95%CI=0.60–0.91, P=0.004; rs9277535, OR=0.72, 95%CI=0.60–0.91, P=0.001). Moreover, in cytokines, there was significant positive association between rs3077 and IL-17 and INF-γ(P=0.037 and P=0.020 respectively; recessive model, P=0.011 and P=0.008, respectively) and the AA genotype predisposed to lower IL-17 and INF-γcompared with other two genotypes. However, none positive connection was found between rs3077 and IL-1 alpha, IL-4, IL-6, IL-10, and IL-23 (P=0.739, 0.624, 0.685, 0.887, and 0.937 correspondingly). None significant positive correlation could be observed between rs9277535 and any cytokines. <h3>Conclusions</h3> HLA-DP polymorphisms (rs3077 and rs9277535) play a protective role in SLE susceptibility. And rs3077 play the role by affecting antigen presentation of HLA class II molecules for CD4+T cells and down-regulating the Th17 signal pathway. <h3>References</h3> Ghodke-Puranik Y, et al. J Autoimmun. 2015; 64:125–136. Kamatani Y1, et al. Nat Genet 2009;41:591–595. <h3>Disclosure of Interest</h3> None declared
Adult Human Blood Leukocytes as a Source of Tissue-Committed Progenitors for Cellular Therapy of Cardiovascular Disease.
Authors: Yael Porat, Valetin Fulga, Danny Belkin, Daphna Shimoni, Adina Belleli, David Czeiger, Damras Tresukosol, Suphachai Chaithiraphan, Alexander Battler
Journal: Blood (2005)
CD123 Immunostaining in Systemic Mastocytosis: Differential Expression in Disease Subgroups and Potential Prognostic Value
Authors: Animesh Pardanani, Kaaren Reichard, Darci Zblewski, Ramy Abdelrahman, Emnet Wassie, William G. Morice, Christopher L. Brooks, Curtis A. Hanson, Ayalew Tefferi, Dong Chen
Journal: Blood (2015)
Safety and Long-Term Efficacy of Maintenance Therapy with Alternating Azacytidine (AZA) and Lenalidomide (Len) Cycles in Elderly (≥ 60) Fit Patients (Pts) with Poor Prognosis AML in First Complete Remission (CR) After LIA Induction. A Phase II Multicentric GOELAMS Trial
Authors: Mathilde Hunault, Nathalie Maillard, Aline Tanguy-Schmidt, Chantal Himberlin, Bachra Choufi, Caroline Bonmati, Marie Anne Couturier, Eric Deconinck, Jean Pierre Marolleau, Frédérique Orsini-Piocelle, Jacques Delaunay, Emmanuelle Tavernier, Christian Récher, Severine Lissandre, Mario Ojeda-Uribe, Laurence Sanhes, Laurent Sutton, Anne Banos, Bruno Lioure, Marc Bernard, Didier Bouscary, Alain Saad, Valérie Rouille, Philippe Guardiola, Isabelle Luquet, Marie C Bene, Francois Dreyfus, Jean-Yves Cahn, Arnaud Pigneux, Norbert Ifrah
Journal: Blood (2015)